CHMP Recommends Approval for Inotersen in hATTR CHMP Recommends Approval for Inotersen in hATTR

Inotersen has won recommendation of the EMA ' s Committee for Medicinal Products for Human Use for treatment of hereditary transthyretin amyloidosis.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news